About Unity Biotechnology
Unity Biotechnology is a company based in San Francisco (United States) founded in 2016. Unity Biotechnology has raised $206 million across 5 funding rounds from investors including Fidelity Investments, WuXi AppTec and Hercules Capital. The company has 16 employees as of December 31, 2024. Unity Biotechnology offers products and services including UBX1325. Unity Biotechnology operates in a competitive market with competitors including Spark Therapeutics, Denali Therapeutics, Poseida Therapeutics, Juno Therapeutics and AskBio, among others.
- Headquarter San Francisco, United States
- Employees 16 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Unity Biotechnology, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$25.99 M (USD)34.8as on Dec 31, 2024
-
EBITDA
-$27.86 M (USD)28.52as on Dec 31, 2024
-
Total Equity Funding
$206 M (USD)
in 5 rounds
-
Latest Funding Round
$80 M (USD), Debt – Conventional
Aug 04, 2020
-
Investors
Fidelity Investments
& 17 more
-
Employee Count
16
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Unity Biotechnology
Unity Biotechnology is a publicly listed company on the OTC with ticker symbol UNBX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Unity Biotechnology
Unity Biotechnology offers a comprehensive portfolio of products and services, including UBX1325.
Drug for treating retinal diseases by targeting cellular senescence.
People of Unity Biotechnology
Unlock access to complete
Unlock access to complete
Funding Insights of Unity Biotechnology
Unity Biotechnology has successfully raised a total of $206M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $80 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Unity Biotechnology
Unity Biotechnology has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, WuXi AppTec and Hercules Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt financing is provided to companies in multiple sectors.
|
Locked | Locked | Locked | |
|
Life-Sciences focused early and growth stage VC firm funding companies in China & the US
|
Locked | Locked | Locked | |
|
Early stage life sciences sectors focused VC firm investing in the US
|
Locked | Locked | Locked |
Investor details for Unity Biotechnology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Unity Biotechnology
Investment portfolio details for Unity Biotechnology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Unity Biotechnology
Detailed financials for Unity Biotechnology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Unity Biotechnology Comparisons
Peer comparison for Unity Biotechnology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Unity Biotechnology
Unity Biotechnology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spark Therapeutics, Denali Therapeutics, Poseida Therapeutics, Juno Therapeutics and AskBio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
Detailed competitors of Unity Biotechnology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Unity Biotechnology
Complete news archive for Unity Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Unity Biotechnology
Unity Biotechnology was founded in 2016.
Unity Biotechnology is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Unity Biotechnology is a funded company, having raised a total of $206M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Unity Biotechnology is 16.
Unity Biotechnology was founded in 2016 and is headquartered in San Francisco, United States. Operations center on the biotechnology sector, where therapeutics are designed to address diseases of aging. Senolytic medicines are developed to selectively eliminate senescent cells, which are implicated in conditions such as osteoarthritis, atherosclerosis, eye diseases, and kidney diseases. A biomarker, p16(Ink4a), is utilized to create targeted approaches like the INK-ATTAC transgene for inducible cell clearance.
Unity Biotechnology's top competitors include Spark Therapeutics, Juno Therapeutics and Generation Bio.
Unity Biotechnology offers UBX1325.
Yes, Unity Biotechnology is publicly traded on OTC under the ticker symbol UNBX.
Unity Biotechnology has 18 investors. Key investors include Fidelity Investments, WuXi AppTec, Hercules Capital, Baillie Gifford, and Arch Venture Partners.
The ticker symbol of Unity Biotechnology is UNBX on OTC.